April 6, 2021

---

Inscripta joins EuropaBio: delivering global biotechnology advances

March 18, 2021

---

Meet the CRISPR pioneers who are making gene editing easy - Inscripta’s Onyx—a “labtop” gene editor—could democratize an array of breakthroughs promised by CRISPR technology (Fast Company)

December 19, 2018

---

In the first year of release, Inscripta’s MAD7 CRISPR enzyme is widely adopted by the gene-editing community - Existing investors contribute an additional $30 million to accelerate tools that will revolutionize genomic research

September 5, 2018

---

Inscripta announces strategic acquisition of Solana Biosciences - Adds former Illumina operations team to develop and commercialize gene-editing technology

July 12, 2018

---

Inscripta granted patents for CRISPR gene-editing systems

February 28, 2018

---

Inscripta raises $55.5 million to advance gene-editing technology - Investment will grow company's expert team, accelerate development and commercialization of gene-editing tools -- including enzymes, reagents, instrumentation, and software